Clinical experience on patient-specific quality assurance for CBCT-based online adaptive treatment plan.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Apr 2023
Historique:
revised: 09 01 2023
received: 22 10 2022
accepted: 12 01 2023
medline: 20 4 2023
pubmed: 3 2 2023
entrez: 2 2 2023
Statut: ppublish

Résumé

Ethos CBCT-based adaptive radiotherapy (ART) system can generate an online adaptive plan by re-optimizing the initial reference plan based on the patient anatomy at the treatment. The optimization process is fully automated without any room for human intervention. Due to the change in anatomy, the ART plan can be significantly different from the initial plan in terms of plan parameters such as the aperture shapes and number of monitor units (MUs). In this study, we investigated the feasibility of using calculation-based patient specific QA for ART plans in conjunction with measurement-based and calculation-based QA for initial plans to establish an action level for the online ART patient-specific QA. A cohort of 98 cases treated on CBCT-based ART system were collected for this study. We performed measurement-based QA using ArcCheck and calculation-based QA using Mobius for both the initial plan and the ART plan for analysis. For online the ART plan, Mobius calculation was conducted prior to the delivery, while ArcCheck measurement was delivered on the same day after the treatment. We first investigated the modulation factors (MFs) and MU numbers of the initial plans and ART plans, respectively. The γ passing rates of initial and ART plan QA were analyzed. Then action limits were derived for QA calculation and measurement for both initial and online ART plans, respectively, from 30 randomly selected patient cases, and were evaluated using the other 68 patient cases. The difference in MF between initial plan and ART-plan was 12.9% ± 12.7% which demonstrates their significant difference in plan parameters. Based on the patient QA results, pre-treatment calculation and measurement results are generally well aligned with ArcCheck measurement results for online ART plans, illustrating their feasibility as an indicator of failure in online ART QA measurements. Furthermore, using 30 randomly selected patient cases, the γ analysis action limit derived for initial plans and ART plans are 89.6% and 90.4% in ArcCheck QA (2%/2 mm) and are 92.4% and 93.6% in Mobius QA(3%/2 mm), respectively. According to the calculated action limits, the ArcCheck measurements for all the initial and ART plans passed QA successfully while the Mobius calculation action limits flagged seven and four failure cases respectively for initial plans and ART plans, respectively. An ART plan can be substantially different from the initial plan, and therefore a separate session of ART plan QA is needed to ensure treatment safety and quality. The pre-treatment QA calculation via Mobius can serve as a reliable indicator of failure in online ART plan QA. However, given that Ethos ART system is still relatively new, ArcCheck measurement of initial plan is still in practice. It may be skipped as we gain more experience and have better understanding of the system.

Identifiants

pubmed: 36729373
doi: 10.1002/acm2.13918
pmc: PMC10113688
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e13918

Informations de copyright

© 2023 University of Texas Southwestern Medical Center. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, LLC on behalf of American Association of Physicists in Medicine.

Références

Australas Phys Eng Sci Med. 2017 Mar;40(1):181-189
pubmed: 27943009
Med Phys. 1998 May;25(5):656-61
pubmed: 9608475
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
J Appl Clin Med Phys. 2023 Apr;24(4):e13918
pubmed: 36729373
Med Phys. 2013 Dec;40(12):121711
pubmed: 24320497
J Appl Clin Med Phys. 2003 Winter;4(1):40-50
pubmed: 12540817
Phys Med Biol. 1997 Jan;42(1):123-32
pubmed: 9015813
Br J Radiol. 2003 Oct;76(910):678-89
pubmed: 14512327
Semin Radiat Oncol. 2019 Jul;29(3):245-257
pubmed: 31027642
J Appl Clin Med Phys. 2020 Jul;21(7):39-48
pubmed: 32368862
J Appl Clin Med Phys. 2019 Oct;20(10):33-42
pubmed: 31471950
Phys Med Biol. 2020 Mar 03;65(5):05TR01
pubmed: 31972556
Med Phys. 2003 Sep;30(9):2455-64
pubmed: 14528967
Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):656-666
pubmed: 32617080

Auteurs

Chenyang Shen (C)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Liyuan Chen (L)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Xinran Zhong (X)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Yesenia Gonzalez (Y)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Justin Visak (J)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Boyu Meng (B)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Enobong Inam (E)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

David Parsons (D)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Andrew Godley (A)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Steve Jiang (S)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Bin Cai (B)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Mu-Han Lin (MH)

Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH